In keeping with previous reports, the therapeutic efficacy of such intervention was dependent on robust CD8+ T cell infiltration of tumors driven primarily by STING activation in, and type I IFN produced by, tumor vascular endothelial cells [31,32,45]. The gene discussed is STING1; the disease is neoplasm.